Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2023-07-31
2023-12-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
NCT06084767
68Ga-NI-FAPI PET/CT: First-in-human Study
NCT06688305
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
NCT07118176
68Ga-FAPI PET/CT in Malignant Tumors
NCT05034146
68Gallium-FAPI PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases
NCT06275477
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To assess feasibility and biodistribution of PET imaging in malignancy using 68Ga-FAPI.
OUTLINE:
Patients receive 68Ga-FAPI intravenously (IV) and then undergo PET/CT approximately 1 hour later.
After completion of study, patients are followed up at 24-72 hours.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
68Ga-FAPI PET/CT
Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.
68Ga-FAPI
68Ga-FAPI is quinoline based PET radiopharmaceutical.
68Ga-FAPI is administered intravenously (IV)
Computed Tomography (CT) scan
Participants will have a CT scan for attenuation correction and anatomic localization of PET data.
Positron Emission Tomography (PET) scan
PET images will be acquired.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
68Ga-FAPI
68Ga-FAPI is quinoline based PET radiopharmaceutical.
68Ga-FAPI is administered intravenously (IV)
Computed Tomography (CT) scan
Participants will have a CT scan for attenuation correction and anatomic localization of PET data.
Positron Emission Tomography (PET) scan
PET images will be acquired.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient must be \> 18 years old
* Patient must be willing and able to provide written informed consent for the trial
* Patient of reproductive potential will have a pregnancy test
Exclusion Criteria
19 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carina A Mari, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford Universiy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University Hospitals and Clinics
Stanford, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VAR0195
Identifier Type: OTHER
Identifier Source: secondary_id
IRB-52129
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.